These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 21048707)

  • 41. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.
    Christopher R; Covington P; Davenport M; Fleck P; Mekki QA; Wann ER; Karim A
    Clin Ther; 2008 Mar; 30(3):513-27. PubMed ID: 18405789
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biomedical applications of accelerator mass spectrometry-isotope measurements at the level of the atom.
    Barker J; Garner RC
    Rapid Commun Mass Spectrom; 1999; 13(4):285-93. PubMed ID: 10097404
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metabolism, pharmacokinetics, and excretion of the substance P receptor antagonist CP-122,721 in humans: structural characterization of the novel major circulating metabolite 5-trifluoromethoxy salicylic acid by high-performance liquid chromatography-tandem mass spectrometry and NMR spectroscopy.
    Colizza K; Awad M; Kamel A
    Drug Metab Dispos; 2007 Jun; 35(6):884-97. PubMed ID: 17360832
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dose-dependent pharmacokinetics and first-pass metabolism of acetaminophen in rats.
    Tone Y; Kawamata K; Murakami T; Higashi Y; Yata N
    J Pharmacobiodyn; 1990 Jun; 13(6):327-35. PubMed ID: 2231264
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics, absolute bioavailability, and disposition of [14C]nefazodone in humans.
    Barbhaiya RH; Dandekar KA; Greene DS
    Drug Metab Dispos; 1996 Jan; 24(1):91-5. PubMed ID: 8825195
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Microdosing for early biokinetic studies in humans.
    Stenström K; Sydoff M; Mattsson S
    Radiat Prot Dosimetry; 2010; 139(1-3):348-52. PubMed ID: 20167793
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Microdosing studies using accelerated mass spectrometry as exploratory investigational new drug trials.
    Bae SK; Shon JH
    Arch Pharm Res; 2011 Nov; 34(11):1789-98. PubMed ID: 22139681
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics and metabolism of nateglinide in humans.
    Weaver ML; Orwig BA; Rodriguez LC; Graham ED; Chin JA; Shapiro MJ; McLeod JF; Mangold JB
    Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):415-21. PubMed ID: 11259325
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Age and dose dependency of the pharmacokinetics and metabolism of bisphenol A in neonatal sprague-dawley rats following oral administration.
    Domoradzki JY; Thornton CM; Pottenger LH; Hansen SC; Card TL; Markham DA; Dryzga MD; Shiotsuka RN; Waechter JM
    Toxicol Sci; 2004 Feb; 77(2):230-42. PubMed ID: 14691203
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
    Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
    Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Microdosing of a Carbon-14 Labeled Protein in Healthy Volunteers Accurately Predicts Its Pharmacokinetics at Therapeutic Dosages.
    Vlaming ML; van Duijn E; Dillingh MR; Brands R; Windhorst AD; Hendrikse NH; Bosgra S; Burggraaf J; de Koning MC; Fidder A; Mocking JA; Sandman H; de Ligt RA; Fabriek BO; Pasman WJ; Seinen W; Alves T; Carrondo M; Peixoto C; Peeters PA; Vaes WH
    Clin Pharmacol Ther; 2015 Aug; 98(2):196-204. PubMed ID: 25869840
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Plasma/blood pharmacokinetics and metabolism after dermal exposure to para-aminophenol or para-phenylenediamine.
    Dressler WE; Appelqvist T
    Food Chem Toxicol; 2006 Mar; 44(3):371-9. PubMed ID: 16239057
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile.
    Balani SK; Xu X; Pratha V; Koss MA; Amin RD; Dufresne C; Miller RR; Arison BH; Doss GA; Chiba M; Freeman A; Holland SD; Schwartz JI; Lasseter KC; Gertz BJ; Isenberg JI; Rogers JD; Lin JH; Baillie TA
    Drug Metab Dispos; 1997 Nov; 25(11):1282-7. PubMed ID: 9351905
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Accelerator MS: its role as a frontline bioanalytical technique.
    Seymour MA
    Bioanalysis; 2011 Dec; 3(24):2817-23. PubMed ID: 22185281
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Accelerator mass spectrometry in pharmaceutical research and development--a new ultrasensitive analytical method for isotope measurement.
    Garner RC
    Curr Drug Metab; 2000 Sep; 1(2):205-13. PubMed ID: 11465084
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Addressing metabolite safety during first-in-man studies using ¹⁴C-labeled drug and accelerator mass spectrometry.
    Lappin G; Seymour M
    Bioanalysis; 2010 Jul; 2(7):1315-24. PubMed ID: 21083242
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Accelerator mass spectrometry (AMS): recent experience of its use in a clinical study and the potential future of the technique.
    Young G; Ellis W; Ayrton J; Hussey E; Adamkiewicz B
    Xenobiotica; 2001; 31(8-9):619-32. PubMed ID: 11569529
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of accelerator mass spectrometry to measure the pharmacokinetics and peripheral blood mononuclear cell concentrations of zidovudine.
    Vuong le T; Ruckle JL; Blood AB; Reid MJ; Wasnich RD; Synal HA; Dueker SR
    J Pharm Sci; 2008 Jul; 97(7):2833-43. PubMed ID: 17854048
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Human Microdosing with Carcinogenic Polycyclic Aromatic Hydrocarbons: In Vivo Pharmacokinetics of Dibenzo[def,p]chrysene and Metabolites by UPLC Accelerator Mass Spectrometry.
    Madeen EP; Ognibene TJ; Corley RA; McQuistan TJ; Henderson MC; Baird WM; Bench G; Turteltaub KW; Williams DE
    Chem Res Toxicol; 2016 Oct; 29(10):1641-1650. PubMed ID: 27494294
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Meeting the MIST regulations: human metabolism in Phase I using AMS and a tiered bioanalytical approach.
    Lappin G; Seymour M; Gross G; Jørgensen M; Kall M; Kværnø L
    Bioanalysis; 2012 Feb; 4(4):407-16. PubMed ID: 22394141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.